Historically, the outcomes for individuals with triple-class refractory and penta-drug refractory
multiple myeloma (MM) have been poor because of a dearth of effective treatment options …

Multiple myeloma (MM) is the second most common hematological malignancy of plasma
cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the …

Several bispecific antibodies (bsAbs) targeting BCMA, GPRC5D, and FcRH5 are in clinical
trials for heavily pretreated multiple myeloma (MM) patients. Teclistamab was approved for …

Teclistamab and other B-cell maturation antigen (BCMA)–targeting bispecific antibodies
(BsAbs) have substantial activity in patients with heavily pretreated multiple myeloma (MM) …

A better understanding of the roles of the adaptive and innate immune systems in the
oncogenesis of cancers including multiple myeloma (MM) has led to the development of …

Simple Summary Bispecific T-cell engagers (BiTEs) and bispecific antibodies (BiAbs) have
emerged as novel therapeutic modalities in the treatment of advanced hematological …

Multiple myeloma (MM) is an incurable neoplasm characterized by significant morbidity and
mortality. Despite advances in treatment, MM patients eventually experienced a relapse of …

Three classes of BCMA-directed therapy (BDT) exist: antibody drug-conjugates (ADCs),
CAR-T, and T-cell engagers (TCEs), each with distinct strengths and weaknesses. To aid …

Bispecific antibodies that engage T cells to target B cell maturation antigen (BCMA) or G
protein-coupled receptor class C group 5 member D (GPRC5D) have demonstrated …

Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells
have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past …